STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

InterCure to Present in Benzinga Cannabis Capital Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

InterCure Ltd (NASDAQ: INCR) announced that CEO Alexander Rabinovitch will present at the Benzinga Cannabis Capital Conference on October 14, 2021, at 1:50 PM ET, with a repeat on October 15 at the same time. Additionally, he will participate in a panel discussion on the expansion of cannabis in European markets on October 15 at 2:10 PM ET. Interested attendees can view the presentation and panel online. InterCure, operating as Canndoc, is Israel’s largest licensed cannabis producer and is recognized for its GMP-certified medical cannabis products.

Positive
  • None.
Negative
  • None.

Insights

Analyzing...

NEW YORK and TORONTO and HERZLIYA, Israel, Oct. 13, 2021 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure" or the “Company”) today announced that Alexander Rabinovitch, CEO of InterCure, will present at the Benzinga Cannabis Capital Conference on Thursday, October 14, 2021 at 1:50pm ET. The presentation will be shown again on October 15th at 1:50pm ET. In addition, Mr. Rabinovitch will participate in a live panel discussion titled, “International Spotlight – Continued Cannabis Expansion in European Markets” on Friday, October 15 at 2:10pm ET. To view the Company presentation, please click the following link: https://youtu.be/8JtjK9-IW80. To watch the live panel discussion, please click the following link: https://youtu.be/9gEdUHA8T0g.

Management will be available for virtual one-on-one meetings with registered conference attendees. To register for the conference, please visit the conference website: https://www.benzinga.com/events/cannabis/october-2021/#who-attends

If you are interested in scheduling a one-on-one meeting with InterCure’s management team, please contact InterCure@kcsa.com.

About InterCure (dba Canndoc)

InterCure (dba Canndoc) (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) is the leading, profitable, and fastest growing cannabis company outside of North America. Canndoc, a wholly owned subsidiary of InterCure, is Israel’s largest licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products. InterCure leverages its market leading distribution network, best in class international partnerships and a high-margin vertically integrated "seed-to-sale" model to lead the fastest growing cannabis global market outside of North America.

For more information, visit: http://www.intercure.co.

To be added to InterCure’s email distribution list, please email InterCure@kcsa.com with “InterCure” in the subject.

Contact:

InterCure Ltd.
Amos Cohen, Chief Financial Officer
amos@canndoc-pharma.com

KCSA Strategic Communications
Investor and Media Relations
InterCure@kcsa.com

 


FAQ

When will InterCure's CEO present at the Benzinga Cannabis Capital Conference?

CEO Alexander Rabinovitch will present on October 14, 2021, at 1:50 PM ET, with a repeat on October 15 at the same time.

What topic will InterCure's CEO discuss at the panel on October 15?

He will discuss the topic of 'International Spotlight – Continued Cannabis Expansion in European Markets' during the panel on October 15 at 2:10 PM ET.

How can I view InterCure's presentation at the Benzinga Cannabis Capital Conference?

You can view the presentation at this link: https://youtu.be/8JtjK9-IW80.

Is InterCure available for one-on-one meetings at the conference?

Yes, InterCure management will be available for virtual one-on-one meetings with registered conference attendees.

What is the significance of InterCure in the cannabis industry?

InterCure (dba Canndoc) is Israel’s largest licensed cannabis producer and one of the fastest-growing cannabis companies outside North America.
Intercure Ltd.

NASDAQ:INCR

INCR Rankings

INCR Latest News

INCR Latest SEC Filings

INCR Stock Data

79.59M
40.27M
26.13%
4.62%
0.07%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
Israel
Herzliya